Eli Lilly and Company $LLY Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 15.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 78,564 shares of the company's stock after selling 14,600 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al's holdings in Eli Lilly and Company were worth $59,944,000 at the end of the most recent reporting period.Get Eli Lilly and Company alerts:FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026A number of other large investors have also modified their holdings of LLY. Lazard Freres Gestion S.A.S. raised its stake in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after acquiring an additional 39 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after acquiring an additional 1,843 shares in the last quarter. Capital Advisors Inc. OK grew its stake in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after acquiring an additional 429 shares in the last quarter. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $54,000. Institutional investors and hedge funds own 82.53% of the company's stock. Eli Lilly and Company Price PerformanceLLY stock opened at $1,075.00 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The business has a fifty day moving average of $1,003.00 and a two-hundred day moving average of $846.93. Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeEli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company's revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year. Eli Lilly and Company Increases DividendThe business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%. Wall Street Analysts Forecast GrowthEli Lilly’s New Drug Data Sets Up a High-Stakes 2026Several research analysts have recently weighed in on LLY shares. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Bank of America reduced their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a "buy" rating on the stock in a research report on Monday, December 15th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an "overweight" rating in a report on Wednesday, December 10th. HSBC reaffirmed a "hold" rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,155.36.View Our Latest Research Report on Eli Lilly and CompanyEli Lilly and Company Company Profile (Free Report)Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.Featured ArticlesFive stocks we like better than Eli Lilly and CompanyThe Best $1 You'll Spend This Holiday SeasonHoliday surprise: $1 gets you everythingAmerica’s “most deplorable” Christmas saleMarket Panic: Trump Just Dropped a Bomb on Your StocksYour family's wealth expires in 2026?Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here